AGTC

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue Washer, President & Chief Executive Officer, and Dave Knop, PhD, Vice President, Process Development and Manufacturing, will participate in the Cantor Fitzgerald “Key Considerations for Gene Therapy Manufacturing and Platforms” virtual panel at 10:00 a.m. ET on Wednesday, October 28, 2020. The panel will focus on the critical components and capabilities to gene therapy manufacturing, including a discussion on AGTC’s proprietary manufacturing processes associated with AAV, and key company catalysts expected over the next 12 months. The call will be moderated by Kristen Kluska, Biotechnology Research Analyst of Cantor Fitzgerald.Presentation Information: Panel: Key Considerations for Gene Therapy Manufacturing and Platforms Date: Wednesday, October 28, 2020 Time: 10:00 a.m. – 11:30 a.m. ETTo register for the event, please click here.About AGTC AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. The Company’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its pre-clinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.IR/PR CONTACTS:  David Carey (IR) or Glenn Silver (PR) Lazar FINN Partners T: (212) 867-1768 or (646) 871-8485 david.carey@finnpartners.com or glenn.silver@finnpartners.comCorporate Contact: Bill Sullivan Chief Financial Officer Applied Genetic Technologies Corporation T: (617) 843-5728 bsullivan@agtc.comStephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 spotter@agtc.com

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness, announce today that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene

The big shareholder groups in Applied Genetic Technologies Corporation (NASDAQ:AGTC) have power over the company...

Toward the end of trading Wednesday, the Dow traded up 2.32% to 28140.09 while the NASDAQ rose 2.87% to 11,159.42. The S&P also rose, gaining 2.44% to 3,413.24.

Midway through trading Wednesday, the Dow traded up 1.90% to 28,024.77 while the NASDAQ rose 2.69% to 11,139.51. The S&P also rose, gaining 2.18% to 3,404.35.

Gainers: Intra-Cellular Therapies (ITCI) +65%, Trillium Therapeutics (TRIL) +36%, Amryt Pharma (AMYT) +25%, BeyondSpring (BYSI) +18%, XTL Biopharmaceuticals (XTLB) +17%.Losers: Co-Diagnostics (CODX) -17%, Applied Genetic Technologies (AGTC) -16%, SCWorx (WORX) -10%, Innate Pharma (IPHA) -7%, PolarityTE (PTE) -5%.

\- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose groups and one control group -\- Data from Group 5 supports use of higher dose level in Phase